Processa Pharmaceuticals, Inc. — Director's Dealing 2023

Jan 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-12-31

Reporting Person: Floyd Robert Michael (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-31	Restricted Stock Units	$0	A	10851	Acquired		Common Stock (10851)	Direct
2023-01-01	Restricted Stock Units	$0	A	55107	Acquired		Common Stock (55107)	Direct
2023-01-01	Restricted Stock Units	$0	A	40690	Acquired		Common Stock (40690)	Direct

Footnotes

F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment? the third anniversary of the award date? a change of control? or the reporting person's death. These restricted stock units vest on date of grant.

F2: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of
employment? the third anniversary of the award date? a change in control, or the reporting persons death,

F3: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24? 01/01/25 and 01/01/26, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death.